In vitro and in vivo venom-inhibition assays identify metalloproteinase-inhibiting drugs as potential treatments for snakebite envenoming by Dispholidus typus

Menzies, S. K.; Clare, R. H.; Xie, C.; Westhorpe, A.; Hall, S. R.; Edge, R. J.; Alsolaiss, J.; Crittenden, E.; Harrison, R. A.; Kool, J.; Casewell, N. R.

doi:10.1101/2022.01.07.475313

bioRxiv · 10.1101/2022.01.07.475313

In vitro and in vivo venom-inhibition assays identify metalloproteinase-inhibiting drugs as potential treatments for snakebite envenoming by Dispholidus typus

Menzies, S. K.·Clare, R. H.·Xie, C.·Westhorpe, A.·Hall, S. R.·Edge, R. J.·Alsolaiss, J.·Crittenden, E.·Harrison, R. A.·Kool, J.·Casewell, N. R.

View original source ↗Export metadata ↓

Abstract

Snakebite envenoming affects more than 250,000 people annually in sub-Saharan Africa. Envenoming by Dispholidus typus (boomslang) results in venom induced consumption coagulopathy, whereby highly abundant prothrombin-activating snake venom metalloproteinases (SVMPs) consume clotting factors and deplete fibrinogen. The only available treatment for D. typus envenoming is the monovalent SAIMR Boomslang antivenom. Treatment options are urgently required because this antivenom is often difficult to source and, at $6,000/vial, typically unaffordable for most snakebite patients. We therefore investigated the in vitro and in vivo preclinical efficacy of four SVMP inhibitors to neutralise the effects of D. typus venom; the matrix metalloproteinase inhibitors marimastat and prinomastat, and the metal chelators dimercaprol and DMPS. The venom of D. typus exhibited an SVMP-driven procoagulant phenotype in vitro. Marimastat and prinomastat demonstrated equipotent inhibition of the SVMP-mediated procoagulant activity of the venom in vitro, whereas dimercaprol and DMPS showed considerably lower potency. However, when tested in preclinical murine models of envenomation, DMPS and marimastat demonstrated partial protection against venom lethality, demonstrated by prolonged survival times of experimental animals, whereas dimercaprol and prinomastat failed to confer any protection at the doses tested. The results presented here demonstrate that DMPS and marimastat show potential as novel small molecule-based therapeutics for D. typus snakebite envenomation. These two drugs have been previously shown to be effective against Echis ocellatus venom induced consumption coagulopathy (VICC) in preclinical models, and thus we conclude that marimastat and DMPS may be valuable early intervention therapeutics to broadly treat VICC following snakebite envenoming in sub-Saharan Africa.

Explore related subjects

pharmacology and toxicology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Menzies, S. K., Clare, R. H., Xie, C., Westhorpe, A., Hall, S. R., Edge, R. J., Alsolaiss, J., Crittenden, E., Harrison, R. A., Kool, J., Casewell, N. R.. 2022-01-07. In vitro and in vivo venom-inhibition assays identify metalloproteinase-inhibiting drugs as potential treatments for snakebite envenoming by Dispholidus typus. https://doi.org/10.1101/2022.01.07.475313

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

bioRxiv2026

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

bioRxiv2022

Inhibition of integrin alpha V (CD51) reduces inflammation and transition to heart failure following pressure overload

BackgroundIntegrins are surface receptors that bind to extracellular matrix ligands and regulate cellular function through mechanical stress-initiated signal transduction. Integrin alpha V (or CD51) is implicated in myocardial fibrosis and anti-CD51 therapy improves cardiac function and cardiac fibrotic remodeling following myocardial infarction. However, their contribution in non-ischemic pressure-overload induced heart failure has not been established. MethodsWe implanted male C57BL/6J wild-type mice with osmotic minipumps containing a combination of AngII (1.44mg/kg/day) and the 1 adrenergic agonist Phenylephrine (PE)(50mg/kg/day) to induce hypertrophic heart failure. Treatment with AngII alone was used as a model of compensated cardiac hypertrophy. Mice treated with PE or saline were used as controls. Animals were treated with daily intraperitoneal injections of the anti-CD51 molecule cilengitide or vehicle. Cardiac echography, flow cytometry, histological, and protein analyses were used to study the development of fibrosis and cardiac adverse remodeling. ResultsMice treated with the combination of AngII and PE showed maladaptive cardiac hypertrophy associated with a fibrotic remodeling and a rapid transition to heart failure. CD51 protein expression and CD51+ cell number were increased in the myocardium of these animals. In contrast, mice treated with AngII alone exhibited compensated cardiac hypertrophy with low levels of fibrosis, no signs of congestive heart failure, and no changes in cardiac CD51 expression as well as CD51+ cell number. Anti-CD51 therapy in mice receiving AngII + PE significantly reduced the transition to heart failure and the development of cardiac fibrosis. Anti-CD51 therapy notably reduced the recruitment of monocyte-derived pro-inflammatory CCR2+ cardiac macrophages, which also showed a high expression of CD51 at their surface. Macrophages sense matrix stiffness and activate a pro-inflammatory response to stiffer substrates, a response that was blunted by anti-CD51 therapy. ConclusionAnti-CD51 therapy reduces the transition to heart failure in response to pressure overload and modulates the pro-inflammatory and deleterious action of CD51+ myeloid cells. We identified CD51 inhibition as a novel therapeutic strategy for reducing the progression of non-ischemic and pressure-dependent heart failure. Clinical perspectivesWhat is new? - We observed a pathologic role of the integrin alpha V in causing a maladaptive response to pressure overload. - A specific pharmacological inhibition of integrin alpha V reduced the transition to heart failure through modulation of the pro-inflammatory and deleterious action of integrin alpha V+ CCR2+ cardiac macrophages. What are the clinical implications? - This study adds to the growing interest in targeting integrins in cardiac disorders by showing a novel immunomodulatory effect. - Integrin alpha V inhibition should be considered as a novel therapeutic strategy for reducing non-ischemic and pressure-dependent heart failure.

pharmacology and toxicology↗